AAAhmed Aliyu Abulfathi

Ahmed Aliyu Abulfathi

*This is an algorithmically generated author record based on publicly available information.

Ahmed Aliyu Abulfathi has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Eric H. Decloedt

    Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University, Cape Town, South Africa

    5 shared publications
  • Helmuth Reuter

    Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town, South Africa

    5 shared publications
  • Andreas H. Diacon

    Task Applied Science, Bellville, South Africa

    4 shared publications
  • Elin M. Svensson

    Department of Pharmacy, Uppsala University , Uppsala, Sweden

    3 shared publications
  • Peter R. Donald

    Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

    3 shared publications
  • Abraham C. van Wyk

    Division of Anatomical Pathology, Tygerberg Hospital, National Health Laboratory Service, Faculty of Medicine and Health Sciences, Stellenbosch University , Cape Town, South Africa

    1 shared publication

Latest Publications

  • Open Access

    Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV

    by Mohammed W. Ali, Sam Nightingale, Tracy Kellermann, John Joska, Alan Winston, Saye Khoo, Joseph F. Standing, Eric H. Decloedt, Ahmed A. Abulfathi

    Characterizing dolutegravir penetration into the central nervous system is important for optimizing human immunodeficiency virus treatment outcomes, yet population‐specific pharmacokinetic data describing cerebrospinal fluid disposition and equilibration kinetics remain lacking. This study characterizes dolutegravir pharmacokinetics in plasma and cerebrospinal fluid to describe the plasma‐to‐cerebrospinal fluid equilibration rate constant and cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient. Sparse pharmacokinetics samples were collected from 121 antiretroviral therapy‐experienced adults who are predominantly overweight or obese (body mass index: 32.2 ± 8.7 kg/m 2 ) receiving daily dolutegravir (50 mg)‐based therapy. The model was developed using nonlinear mixed‐effects modeling in NONMEM. Plasma dolutegravir pharmacokinetics were best described by a one‐compartment model with first‐order absorption and elimination. The population estimate for apparent oral clearance was 1.38 L/h/70 kg. Cerebrospinal fluid data were modeled using a sequential approach with a hypothetical effect compartment linked to plasma to estimate equilibration kinetics and relative cerebrospinal fluid exposure at steady‐state. Key cerebrospinal fluid penetration parameters included a plasma‐to‐cerebrospinal fluid equilibration rate constant of 0.38 h −1 , corresponding to an equilibration half‐life of 1.82 h, and a cerebrospinal fluid‐to‐plasma pseudo‐partition coefficient of 0.0015, indicating 0.15% cerebrospinal fluid penetration relative to plasma. Post hoc estimated area under the concentration‐time curve (0–24) demonstrated a moderate inverse correlation with body mass index ( r = −0.34), indicating that dolutegravir exposure decreases with increasing body mass index. The model revealed rapid plasma‐to‐cerebrospinal fluid equilibration kinetics with low steady‐state cerebrospinal fluid penetration in this predominantly overweight and obese population.

  • Open Access

    A Pharmacometric Workflow for Resolving Model Instability in Model Use‐Reuse Settings

    by Stephen B. Duffull, Daniel F. B. Wright, Xiao Zhu, Xin Liu, Ahmed Abulfathi, Hailemichael Hishe

    The development of fit‐for‐purpose pharmacokinetic‐pharmacodynamic (PKPD) models based on clinical and pre‐clinical data is a critically important process in model informed drug development. This process is often hampered by modeling stability issues that are often multifactorial in nature and difficult to overcome, leading to protracted model building and arbitrary simplification of the model. This tutorial provides a heuristic workflow to help identify and resolve issues relating to model instability. The approach is centered on analyses undertaken using NONMEM, but the concepts can be generalized to other software used for population analysis of pharmacokinetics (PK) or PKPD data.


  • Open Access

    Drug concentration at the site of disease in children with pulmonary tuberculosis

    by Elisa Lopez-Varela, Ahmed A. Abulfathi, Natasha Strydom, Pierre Goussard, Abraham C. van Wyk, Anne Marie Demers, Anneen Van Deventer, Anthony J. Garcia-Prats, Johannes van der Merwe, Matthew Zimmerman, et al.

    Background: Current TB treatment for children is not optimized to provide adequate drug levels in TB lesions. Dose optimization of first-line antituberculosis drugs to increase exposure at the site of disease could facilitate more optimal treatment and future treatment-shortening strategies across the disease spectrum in children with pulmonary TB. Objectives: To determine the concentrations of first-line antituberculosis drugs at the site of disease in children with intrathoracic TB. Methods: We quantified drug concentrations in tissue samples from 13 children, median age 8.6 months, with complicated forms of pulmonary TB requiring bronchoscopy or transthoracic surgical lymph node decompression in a tertiary hospital in Cape Town, South Africa. Pharmacokinetic models were used to describe drug penetration characteristics and to simulate concentration profiles for bronchoalveolar lavage, homogenized lymph nodes, and cellular and necrotic lymph node lesions. Results: Isoniazid, rifampicin and pyrazinamide showed lower penetration in most lymph node areas compared with plasma, while ethambutol accumulated in tissue. None of the drugs studied was able to reach target concentration in necrotic lesions. Conclusions: Despite similar penetration characteristics compared with adults, low plasma exposures in children led to low site of disease exposures for all drugs except for isoniazid.


  • Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens

    by Ahmed A. Abulfathi, Piyanan Assawasuwannakit, Peter R. Donald, Andreas H. Diacon, Helmuth Reuter, Elin M. Svensson

    Purpose Para-aminosalicylic acid (PAS) is currently one of the add-on group C medicines recommended by the World Health Organization for multidrug-resistant tuberculosis treatment. At the recommended doses (8–12 g per day in two to three divided doses) of the widely available slow-release PAS formulation, studies suggest PAS exposures are lower than those reached with older PAS salt formulations and do not generate bactericidal activity. Understanding the PASER dose-exposure–response relationship is crucial for dose optimization. The objective of our study was to establish a representative population pharmacokinetics model for PASER and evaluate the probability of bactericidal and bacteriostatic target attainment with different dosing regimens. Methods To this end, we validated and optimized a previously published population pharmacokinetic model on an extended dataset. The probability of target attainment was evaluated for once-daily doses of 12 g, 14 g, 16 g and 20 g PASER. Results The final optimized model included the addition of variability in bioavailability and allometric scaling with body weight on disposition parameters. Peak PAS concentrations over minimum inhibitory concentration of 100, which is required for bactericidal activity are achieved in 53%, 65%, 72% and 84% of patients administered 12, 14, 16 and 20 g once-daily PASER, respectively, when MIC is 1 mg/L. For the typical individual, the exposure remained above 1 mg/L for ≥ 98% of the dosing interval in all the evaluated PASER regimens. Conclusion The pharmacokinetic/pharmacodynamic parameters linked to bactericidal activity should be determined for 14 g, 16 g and 20 g once-daily doses of PASER.


  • The pharmacokinetics of para‐aminosalicylic acid and its relationship to efficacy and intolerance

    by Ahmed A. Abulfathi, Peter R. Donald, Kim Adams, Elin M. Svensson, Andreas H. Diacon, Helmuth Reuter

    Following its introduction as an antituberculosis agent close to 75 years ago, the use of para‐aminosalicylic acid (PAS) has been limited by gastrointestinal intolerance and multiple formulations were produced in attempts to reduce its occurrence. More recently, an enteric‐coated, granular, slow‐release PAS formulation (PASER) was introduced and is now in wide‐spread use for the treatment of drug‐resistant tuberculosis. The current PASER dosing regimen is based on recommendations derived from older studies using a variety of different PAS formulations and relegate PAS to a role as an exclusively bacteriostatic agent. However, there is ample evidence that if sufficiently high serum concentrations are reached, PAS can be bactericidal and that intolerance following once daily dosing, that aids the achievement of such concentrations, is no worse than that following intermittent daily dosing. In particular, prevention of resistance to companion drugs appears to be dependent on the size of the single dose, and hence the peak concentrations, and not on maintaining serum levels consistently above minimum inhibitory concentration. We present a narrative review of the development of PAS formulations, dosing practices, and published data regarding pharmacokinetics and pharmacodynamics and the relationship of PAS dosage to intolerance and efficacy. Our conclusions suggests that we are at present not using PAS to its maximum ability to contribute to regimen efficacy and protect companion drugs.


  • Pharmacokinetics of Para‐Aminosalicylic Acid and Its 2 Major Metabolites: A Potential Relationship to the Development of Gastrointestinal Intolerance

    by Kim T. Adams, Peter R. Donald, Ahmed A. Abulfathi, Andreas H. Diacon, Marietjie A. Stander, Helmuth Reuter

    Para‐aminosalicylic acid (PAS), often the last drug remaining for treatment of drug‐resistant tuberculosis, is notorious for causing gastrointestinal intolerance; however, the cause of PAS intolerance is uncertain. The objective of this study was to assess relationships between peak concentrations of PAS administered as a granular slow‐release enteric coated formulation, and its metabolites acetyl‐PAS and glycine‐PAS, and intolerance. PAS and its metabolites were measured in 29 adult patients with drug‐resistant tuberculosis at Brooklyn Hospital, Cape Town, randomized to receive granular slow‐release enteric‐coated PAS 4 g twice daily or 8 g once daily for 1 week, followed by the alternative regimen. Concentrations of PAS and its metabolites were determined by liquid chromatography and tandem mass spectrometry, and a visual analogue scale evaluated intolerance. Spearman's correlation test assessed the relationship between maximum plasma concentrations (Cmax) and intolerance scores. A large interindividual variability was observed for the PAS Cmax (40.42‐68.55 mg/L) following 4 g twice daily; (62.69‐102.41 mg/L) for 8 g once daily and a similar wide Cmax range found for the metabolites acetyl‐PAS and glycine‐PAS. Twenty‐six patients reported at least 1 intolerance episode, but most visual analogue scale scores clustered around 0. Significant inverse associations were found between acetyl‐PAS Cmax and bloating (rho = –0.448; P = .025) and diarrhea (rho = –0.407; P = .044) for the twice‐daily regimen and a similar inverse association found for glycine‐PAS and diarrhea (rho = –0.412; P = .041). Plasma concentrations of the metabolites did not correlate with the occurrence of gastrointestinal symptoms, but higher metabolite concentrations correlated with lower intolerance scores; slow metabolism of PAS and its continued presence in the intestinal tract may be the main cause of intolerance.


  • Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

    by Ahmed Aliyu Abulfathi, Eric H. Decloedt, Elin M. Svensson, Andreas H. Diacon, Peter Donald, Helmuth Reuter

    The introduction of rifampicin (rifampin) into tuberculosis (TB) treatment five decades ago was critical for shortening the treatment duration for patients with pulmonary TB to 6 months when combined with pyrazinamide in the first 2 months. Resistance or hypersensitivity to rifampicin effectively condemns a patient to prolonged, less effective, more toxic, and expensive regimens. Because of cost and fears of toxicity, rifampicin was introduced at an oral daily dose of 600 mg (8–12 mg/kg body weight). At this dose, clinical trials in 1970s found cure rates of ≥ 95% and relapse rates of < 5%. However, recent papers report lower cure rates that might be the consequence of increased emergence of resistance. Several lines of evidence suggest that higher rifampicin doses, if tolerated and safe, could shorten treatment duration even further. We conducted a narrative review of rifampicin pharmacokinetics and pharmacodynamics in adults across a range of doses and highlight variables that influence its pharmacokinetics/pharmacodynamics. Rifampicin exposure has considerable inter- and intra-individual variability that could be reduced by administration during fasting. Several factors including malnutrition, HIV infection, diabetes mellitus, dose size, pharmacogenetic polymorphisms, hepatic cirrhosis, and substandard medicinal products alter rifampicin exposure and/or efficacy. Renal impairment has no influence on rifampicin pharmacokinetics when dosed at 600 mg. Rifampicin maximum (peak) concentration (Cmax) > 8.2 μg/mL is an independent predictor of sterilizing activity and therapeutic drug monitoring at 2, 4, and 6 h post-dose may aid in optimizing dosing to achieve the recommended rifampicin concentration of ≥ 8 µg/mL. A higher rifampicin Cmax is required for severe forms TB such as TB meningitis, with Cmax ≥ 22 μg/mL and area under the concentration–time curve (AUC) from time zero to 6 h (AUC6) ≥ 70 μg·h/mL associated with reduced mortality. More studies are needed to confirm whether doses achieving exposures higher than the current standard dosage could translate into faster sputum conversion, higher cure rates, lower relapse rates, and less mortality. It is encouraging that daily rifampicin doses up to 35 mg/kg were found to be safe and well-tolerated over a period of 12 weeks. High-dose rifampicin should thus be considered in future studies when constructing potentially shorter regimens. The studies should be adequately powered to determine treatment outcomes and should include surrogate markers of efficacy such as Cmax/MIC (minimum inhibitory concentration) and AUC/MIC.


  • Evaluation of the Effectiveness of Dose Individualization to Achieve Therapeutic Vancomycin Concentrations

    by Ahmed A. Abulfathi, Maxwell Chirehwa, Bernd Rosenkranz, Eric H. Decloedt

    The glycopeptide antibiotic vancomycin is used for treatment of methicillin‐resistant Gram‐positive cocci. Adequate vancomycin plasma concentrations are related to bacterial cure. However, inter‐ and intrapatient variability make it difficult to achieve therapeutic vancomycin concentrations. The primary objective of this study was to determine the effectiveness of using computerized therapeutic drug monitoring (TDM) to assist in achieving therapeutic vancomycin concentrations at a tertiary hospital in South Africa. This was a 2‐period study consisting of a retrospective 1‐month observational period followed by a prospective 1‐month period in which computerized TDM was implemented as an intervention to assist with vancomycin dose individualization. During the prospective period, all vancomycin TDM results were followed by dosage individualization using computerized TDM. The retrospective period included 77 patients with 292 vancomycin concentrations: 69% (53/77) adult and 31% (24/77) pediatric patients. The prospective period included 80 patients with 217 vancomycin concentrations measured: 69% (55/80) adult and 31% (25/80) pediatric patients. Fewer vancomycin TDM data were requested during the prospective period with a median (interquartile range) of 2 (1–3) samples per patient compared with 3 (1–5) samples per patient during the retrospective period. The odds ratio of achieving therapeutic trough concentrations was 3.63 (95%CI 1.81–7.3) in the prospective period when TDM‐adjusted vancomycin dosing and appropriate TDM procedures were applied. The use of computerized TDM resulted in a higher frequency of therapeutic vancomycin concentrations in a middle‐income setting. Trough vancomycin concentrations alone correlate poorly with the area under plasma concentration‐time curve from 0 to 24 hours.


  • Open Access

    Angio-oedema associated with colistin

    by A A Abulfathi, T Greyling, M Makiwane, M Esser, E Decloedt

    A 50-year-old woman known to have type 1 diabetes mellitus presented with a rare case of angio-oedema associated with colistin use. The angio-oedema was temporally associated with the use and discontinuation of colistin with the reasonable exclusion of important differential diagnoses. Pseudoallergy may be a probable underlying mechanism. However, we cannot exclude the possibility of hereditary angio-oedema type 2 or 3, or that her concomitant medications (particularly enalapril) and her renal impairment contributed to the risk and severity of her angio-oedema.


  • Open Access

    Health-related quality of life and its association with medication adherence in active pulmonary tuberculosis– a systematic review of global literature with focus on South Africa

    by Tanja Kastien-Hilka, Ahmed Abulfathi, Bernd Rosenkranz, Bryan Bennett, Matthias Schwenkglenks, Edina Sinanovic

    Tuberculosis (TB) is a leading cause of morbidity and mortality in South Africa. Clinical parameters are important objective outcomes in TB; however they often are not directly correlated with subjective well-being of the patient, but can be assessed using patient-reported outcome (PRO) measures. Health-related quality of life (HRQOL) is a specific PRO generally multi-dimensional in nature and includes physical, mental and social health domains. The inclusion of HRQOL PROs in trials and clinical practice can provide additional information beyondclinical and microbiological parameters. Furthermore, HRQOL may be associated with medication adherence. This review focuses on patient-reported HRQOL and its association with medication adherence in TB patients in South Africa. A comprehensive search strategy was developed focusing on the impact of TB on patient-reported HRQOL,the existence of a conceptual framework of TB-specific HRQOL, determinants of medication adherence and the association of HRQOL with medication adherence. Data were extracted from all identified articles and additionaldata extraction was performed by two independent reviewers with special focus on longitudinal studies in order to understand changes of HRQOL and adherence over time. Research gaps were identified with regard to patient-reported HRQOL and medication adherence. A total of 66 articles met the eligibility criteria. Ten HRQOL studies and one adherence study used a longitudinal design, none of these in South Africa. A variety of different generic and disease-specific HRQOL measures were identified in the articles. In South Africa four HRQOL and five adherence studies (non-longitudinal) were published. Similar factors (socio-demographic, socio-economic, disease-related, therapy-related and psycho-social aspects) affect HRQOL and adherence. Although standard TB treatment improved all health domains, psychological well-being and social functioning remained impaired in microbiologically cured patients after treatment. While evidence of TB impact on HRQOL and medication adherence and their association exists, it is verylimited for the South African situation. No valid and reliable TB-specific HRQOL measures were identified in this systematicreview. An assessment of HRQOL in TB patients in South Africa is required as this may assist with improving current disease management programmes, medication adherence and national treatment guidelines.